Compare RGS & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGS | ATYR |
|---|---|---|
| Founded | 1922 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.3M | 79.2M |
| IPO Year | 1991 | 2015 |
| Metric | RGS | ATYR |
|---|---|---|
| Price | $25.84 | $0.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 5.7K | ★ 2.0M |
| Earning Date | 02-11-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.05 | N/A |
| EPS | ★ 45.08 | N/A |
| Revenue | ★ $223,032,000.00 | $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18,728.88 |
| P/E Ratio | $0.58 | ★ N/A |
| Revenue Growth | ★ 13.98 | N/A |
| 52 Week Low | $15.00 | $0.64 |
| 52 Week High | $31.50 | $7.29 |
| Indicator | RGS | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 35.83 | 43.23 |
| Support Level | $24.98 | $0.71 |
| Resistance Level | $27.75 | $0.76 |
| Average True Range (ATR) | 0.77 | 0.05 |
| MACD | -0.31 | 0.01 |
| Stochastic Oscillator | 11.66 | 22.17 |
Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.